Lupin shares in focus after launching Formoflo-G MDI, worlds first triple-combination drug for COPD
Why did Lupin Ltd shares jump today?
Lupin Ltd shares rose 0.45% today, trading at ₹2012.0 as of 10:09 AM on Tuesday. The uptick comes after the company announced a major breakthrough in the respiratory care segment. Lupin launched Formoflo-G® MDI, the world's first fixed-dose triple combination metered-dose inhaler (MDI) designed for the management of Chronic Obstructive Pulmonary Disease (COPD) in India. The product received approval from the Drug Controller General of India (DCGI) and represents a significant step forward in respiratory healthcare.
COPD is a long-term lung condition that affects millions of people worldwide, and effective treatment options have been limited. With Formoflo-G® MDI, Lupin has introduced a combined therapy in a single inhaler, making it easier for patients to manage their condition without needing multiple devices. This kind of innovative, patient-friendly approach is exactly what the healthcare market values, and investors are responding positively to the company's ability to bring cutting-edge therapies to market.
The launch strengthens Lupin's position in the respiratory segment and highlights the company's continued focus on developing differentiated products. Such world-first innovations often open up new revenue opportunities and can drive future growth. The market appears to have priced in this positive development, as reflected in the steady rise in Lupin's share price following the announcement.
What does Lupin Ltd do?
Lupin Limited, headquartered in Mumbai, India, is a pharmaceutical company that develops and brings new medicines to market. The company's products are sold across its key markets, including India, where it is listed on both the National Stock Exchange of India under the symbol LUPIN and BSE Limited under Scrip Code 500257; its shares also trade on international markets under the tickers LUPIN.BO and Bloomberg's LPCIN. The firm maintains a corporate identity under its registered CIN and operates a dedicated website at lupin.com, with its corporate leadership represented by its Company Secretary and Compliance Officer, Amit Kumar Gupta.
Lupin is actively pursuing innovation in respiratory care. On October 6, 2026, the company announced the launch of Formoflo-G® MDI, described as the world's first fixed-dose triple combination drug for the management of COPD. The announcement was made through a formal press release addressed to the National Stock Exchange of India Limited and BSE Limited, submitted as a disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and made available for dissemination to the investing public.
Lupin Ltd Financials
In CroresLupin Ltd's financial performance shows a mixed trend across the two quarters. Revenue increased from ₹7,391.91 Crores in March 2026 to ₹8,217.23 Crores in June 2026, representing a growth of ₹825.32 Crores, or approximately 11.16%, reflecting a notable upward trajectory in the company's top-line earnings. In contrast, profit declined over the same period, moving from ₹1,460.34 Crores in March 2026 to ₹1,415.0 Crores in June 2026, a decrease of ₹45.34 Crores, or roughly 3.11%. This divergence between rising revenue and falling profit suggests that while Lupin successfully expanded its sales volume, the company's profitability was under pressure, potentially due to higher operating costs, increased expenses, or other headwinds impacting margins during the June 2026 quarter.
Lupin Ltd Shareholding Pattern
Promoter holding stands at 46.85% of the total share capital. Foreign Institutional Investors (FIIs) hold 22.42% stake in the company, while Domestic Institutional Investors (DIIs) hold 24.65%. Public shareholders hold the remaining 6.08% stake in Lupin Ltd.
Lupin Ltd FAQs
Q: Why did Lupin shares jump 0.45% today?
Lupin Launches Formoflo-G MDI, World''s First Fixed-dose Triple Combination Drug for COPD Management.. This corporate action caught investor attention, leading to increased trading activity in the stock.
Q: What is the shareholding pattern of Lupin Ltd?
As per the latest data, promoters hold 46.85% stake in Lupin Ltd, while FII holding stands at 22.42%. Domestic institutional investors hold 24.65%, and public shareholders account for 6.08% of the equity.
Q: What is the current stock price of Lupin Ltd?
Lupin Ltd shares are currently trading at ₹2012.0, recording a gain of 0.45% from the previous close.
Q: What is the market capitalization of Lupin Ltd?
The company currently has a market capitalization of ₹91941.95 crore, reflecting its valuation in the Indian equity market.